Kardiologiya最新文献

筛选
英文 中文
Results of the Registry of Patients With Atrial Tachyarhythmias After Interventional Treatment (RPATIT). 介入治疗(RPATIT)后房性心动过速患者登记结果。
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-04-30 DOI: 10.18087/cardio.2025.4.n2803
O R Eshmatov, R E Batalov, M S Khlynin, E A Archakov
{"title":"Results of the Registry of Patients With Atrial Tachyarhythmias After Interventional Treatment (RPATIT).","authors":"O R Eshmatov, R E Batalov, M S Khlynin, E A Archakov","doi":"10.18087/cardio.2025.4.n2803","DOIUrl":"https://doi.org/10.18087/cardio.2025.4.n2803","url":null,"abstract":"<p><p>Aim      To study the long-term clinical profile of safety and efficacy of anticoagulant therapy (ACT) in patients with atrial tachyarrhythmias (AT) after interventional treatment.Material and methods  A total of 5,611 medical records of patients managed in the Department of Surgical Treatment of Complex Heart Rhythm Disorders and Electrical Pacing of the Cardiology Research Institute of Tomsk National Research Medical Center (TNRMC) from 01.01.2017 through 31.12.2019 was analyzed. The study included 1,342 of the patients with various forms of AT who underwent the catheter treatment for heart rhythm disorders.Results The administration of ACT to patients with AT after the interventional treatment is safe, since the combined use of an invasive strategy and ACT does not increase the risk of major and minor bleeding. The effective intervention allows significantly reducing the risk of ischemic stroke in patients with paroxysmal and persistent atrial fibrillation and virtually completely excluding the likelihood of other thromboembolic complications.Conclusion      Successful radiofrequency ablation/cryoballoon ablation of atrial fibrillation foci significantly reduces the risk of ischemic stroke, while the invasive strategy does not increase the risk of major and minor bleeding.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"37-41"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipoprotein(a) and Its Association with Coronary Heart Disease: Data from a Large Cohort in the Russian. 脂蛋白(a)及其与冠心病的关系:来自俄罗斯大队列的数据
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-04-30 DOI: 10.18087/cardio.2025.4.n2866
G A Konovalov, Z I Khutaeva, M B Mukhtarov, V L Averkiev, O N Korneeva, O S Kalacheva, V S Rabicheva
{"title":"Lipoprotein(a) and Its Association with Coronary Heart Disease: Data from a Large Cohort in the Russian.","authors":"G A Konovalov, Z I Khutaeva, M B Mukhtarov, V L Averkiev, O N Korneeva, O S Kalacheva, V S Rabicheva","doi":"10.18087/cardio.2025.4.n2866","DOIUrl":"https://doi.org/10.18087/cardio.2025.4.n2866","url":null,"abstract":"<p><p>Aim      To study the distribution of lipoprotein(a) [Lp(a)] concentrations in a large sample of the adult population of the Russian Federation depending on gender and age, and the Lp(a) association with the incidence of ischemic heart disease (IHD).Material and methods  Cross-analysis of electronic medical records of patients older than 18 years managed in the MEDSI Group of Companies as a part of primary and secondary prevention.Results Among 73,763 patients, the mean age was 45 [37; 56] years, 57.3% were women. The median Lp(a) concentration was 11 [6.0; 32.0] mg/dl. The median Lp(a) concentration in women was higher than in men, 12.0 and 10.5 mg/dl, respectively (p&lt;0.0001). Hyperlipoproteinemia(a) (Lp(a) &gt;30 mg/dl) was diagnosed in 26% (n=19,188) of patients (95% confidence interval (CI): 25.7-26.3), statistically significant association with IHD was observed over the entire range of elevated Lp(a) concentrations (p&lt;0.001). Extremely high Lp(a) concentrations exceeding 180 mg/dl were detected in 852 (1.2%) of patients, and 210 of them were diagnosed with IHD. Logistic regression analysis confirmed a significant association between Lp(a) concentrations and IHD (odds ratio (OR) 1.006; 95% CI 1.003-1.008; p&lt;0.001). With an increase in Lp(a) by 1 mg/dl, the likelihood of having IHD increased by 1.006 times. With Lp(a) &gt;50 mg/dL, the likelihood of IHD increased by 1.32 times (OR 1.320; 95% CI 1.254-1.390; p&lt;0.001), with Lp(a) &gt;180 mg/dL, by 2.06 times (OR 2.058; 95% CI 1.758-2.408), and with Lp(a) 30-50 mg/dL, by 1.1 times (OR 1.100; 95% CI 1.017-1.188; p=0.016).Conclusion      Every fourth person has an elevated Lp(a) concentration, which determines a high risk of developing cardiovascular diseases. Taking into account the accumulated data, early assessment of the Lp(a) concentration is necessary for all adults.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"3-9"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144034458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The Effect of Metformin on Short-Chain Fatty Acid Levels in Patients with Chronic Heart Failure, Prediabetes, and Sarcopenia]. 二甲双胍对慢性心力衰竭、前驱糖尿病和肌肉减少症患者短链脂肪酸水平的影响。
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-04-30 DOI: 10.18087/cardio.2025.4.n2836
A V Klimova, A V Sokolova, D O Dragunov, N P Kulagina, T A Shmigol, V V Negrebetsky, Ya V Golubev, G P Arutyunov
{"title":"[The Effect of Metformin on Short-Chain Fatty Acid Levels in Patients with Chronic Heart Failure, Prediabetes, and Sarcopenia].","authors":"A V Klimova, A V Sokolova, D O Dragunov, N P Kulagina, T A Shmigol, V V Negrebetsky, Ya V Golubev, G P Arutyunov","doi":"10.18087/cardio.2025.4.n2836","DOIUrl":"10.18087/cardio.2025.4.n2836","url":null,"abstract":"<p><p>Aim    To evaluate the effect of extended-release metformin (metformin long) on plasma concentrations of short-chain fatty acids (SCFA), physical performance and muscle strength in patients with chronic heart failure (CHF), sarcopenia and prediabetes.Material and methods    The study included 27 patients (mean age 68±9.8 years) with CHF, sarcopenia and prediabetes randomized into the groups of intervention (n=14) (metformin long + healthy lifestyle, HLS) and control (n=13) (HLS). Measurement of SCFA (C3, iC4, C4, αC5, βC5, C5, iC6, C6) concentrations, bioimpedancemetry, Short Physical Performance Battery (SPPB) test, and dynamometry were performed at the beginning of the study and after 6 months. R language and RStudio software were used for statistical analysis.Results    The study groups were comparable in clinical characteristics. The SCFA concentrations were significantly increased, except for iC6. After 6 months of treatment, the SCFA concentrations were decreased, except for C5, iC6, C3. Metformin long improved the physical performance and strength index. The median SPPB score in the control group was 4 [3.0; 9.5] and in the metformin group, 9 [7.25; 9.75], p = 0.0014. In the control group, the change in Δ strength index was -4.65 [-11.09; 17.66], in the metformin group, 18.75 [8.17; 33.03], p = 0.031.Conclusion    Metformin exerts a beneficial effect on plasma SCFA and physical performance in patients with prediabetes, CHF, and sarcopenia.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"46-51"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Catecholaminergic Polymorphic Ventricular Tachycardia Caused by a Homozygous Pathogenic Variant in Calsequestrin 2 Gene]. Calsequestrin 2基因纯合致病变异引起的儿茶酚胺能多态性室性心动过速
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-04-30 DOI: 10.18087/cardio.2025.4.n2877
S M Komissarova, N N Chakova, S S Niyazova, T V Dolmatovich, T A Troyanova-Shchutskaia, N M Rineiska
{"title":"[Catecholaminergic Polymorphic Ventricular Tachycardia Caused by a Homozygous Pathogenic Variant in Calsequestrin 2 Gene].","authors":"S M Komissarova, N N Chakova, S S Niyazova, T V Dolmatovich, T A Troyanova-Shchutskaia, N M Rineiska","doi":"10.18087/cardio.2025.4.n2877","DOIUrl":"https://doi.org/10.18087/cardio.2025.4.n2877","url":null,"abstract":"<p><p>The article presents a clinical case of a 19-year-old patient with catecholaminergic polymorphic ventricular tachycardia caused by the pathogenic homozygous variant p.Ile193Asnfs*17 (rs397516643) in the CASQ2 gene, the early manifestations of which were recurrent syncope during emotional stress, supraventricular and polymorphic ventricular arrhythmias in the absence of structural changes in the heart. The article showed the evolution of heart rhythm disorders during the observation period. The authors discussed the issues of risk stratification for sudden cardiac death and the strategy for its prevention in this pathology.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"57-64"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Prospective Observation Study of Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases. 肺动脉高压合并结缔组织病的长期前瞻性观察研究
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-04-30 DOI: 10.18087/cardio.2025.4.n2919
A V Volkov, N N Yudkina, E L Nasonov
{"title":"Long-Term Prospective Observation Study of Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases.","authors":"A V Volkov, N N Yudkina, E L Nasonov","doi":"10.18087/cardio.2025.4.n2919","DOIUrl":"10.18087/cardio.2025.4.n2919","url":null,"abstract":"<p><p>Aim    Analysis of survival and the impact of etiology, adverse prognosis factors, and therapy on the survival of patients with pulmonary arterial hypertension associated with immune-mediated inflammatory rheumatic diseases (PAH-IIRD).Material and methods    The study included 95 patients: 76 with systemic scleroderma (SSc), 9 with mixed connective tissue disease (MCTD), 8 with systemic lupus erythematosus (SLE), one with rheumatoid arthritis, and one with Sjogren's disease with diagnosed PAH. All patients were prescribed PAH-specific therapy and followed up for at least 5 years during this treatment. The endpoint of the study was all-cause death.Results    During the 5-year follow-up period, 37 patients with PAH-SSc and 4 with PAH-MCTD (43%) died. There were no fatal outcomes in PAH-SLE. One-, two-, three-, and five-year survival rates in the overall group of patients were 91%, 80%, 73%, and 57%, respectively. In patients with PAH-SSc, one-, two-, three-, and five-year survival rates were worse than in PAH-MCTD (88%, 76%, 68%, 51% and 100%, 89%, 89%, 56%, respectively). The factors associated with a fatal outcome included age, gender, functional class, 6-minute walk test distance, right atrial pressure, cardiac output, pulmonary vascular resistance, and biomarker (uric acid and N-terminal pro-brain natriuretic peptide) concentrations. The use of macitentan and/or riociguat, as monotherapy or in combination with another PAH-specific drug, significantly reduced the 5-year risk of fatal outcome (OR 0.38 [0.16; 0.89], p=0.027).Conclusion    The survival of patients with PAH-IIRD remains low. Further studies aimed at finding new pathogenetic targets are needed; the use of modern PAH-specific drugs (macitentan and/or riociguat) modifies the course of the disease, increasing the survival.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"23-30"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening Possibilities for Fabry Disease: Experience of the Ryazan Region. 法布里病筛查的可能性:梁赞地区的经验。
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-04-30 DOI: 10.18087/cardio.2025.4.n2898
Yu V Abalenikhina, A V Shchulkin, E V Filippov, E A Smirnova, O V Ponomareva
{"title":"Screening Possibilities for Fabry Disease: Experience of the Ryazan Region.","authors":"Yu V Abalenikhina, A V Shchulkin, E V Filippov, E A Smirnova, O V Ponomareva","doi":"10.18087/cardio.2025.4.n2898","DOIUrl":"https://doi.org/10.18087/cardio.2025.4.n2898","url":null,"abstract":"<p><p>Aim      To evaluate the possibilities of screening for Fabry disease (FD) in a particular region of the Russian Federation.Material and methods  This was an open prospective non-comparative study. The screening included patients with left ventricular (LV) hypertrophy &gt;13 mm without severe hypertension; patients who had suffered stroke without an apparent cause; patients with peripheral pain syndrome associated with distal polyneuropathy with predominant damage to small fibers; patients with signs of FD during physical examination; coarse facial features; angiokeratomas (inner thighs, hands, abdomen, oral mucosa); thermoregulation disorders; chronic kidney disease. Screening for FD in the region was accompanied by educational activities on the diagnosis of the most common rare (orphan) diseases in adults; also, the routing of patients with FD was mapped out. General practitioners and cardiologists also had an opportunity to send dried blood spots directly to reference centers for the diagnosis of FD and other diseases associated with LV hypertrophy.Results Of the 125 patients who underwent the screening, only 4 had a reduced alpha-galactosidase A activity (to 1.71; 0.78; 0.44; 0.60 μmol/l/h), and in one of them, the diagnosis of FD was genetically confirmed. Five patients with \"atypical\" FD were identified during the work on FD diagnostics in the region, due to the improved knowledge about the signs of orphan diseases, as well as the mapped-out patient routing with the possibility to evaluate the panel of enzyme activity and metabolites of the diseases associated with LV hypertrophy.Conclusion      During the screening examination of 125 patients with suspected FD, it was possible to confirm the diagnosis in one (0.8%) patient. To increase the effectiveness of screening, it is necessary not only to provide the opportunity for diagnosing enzymes and metabolites, but also to conduct educational programs with the formation of routing for patients with suspected orphan diseases associated with LV hypertrophy.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"31-36"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Relationship between Phenotypic Classification and Inflammatory Parameters in Patients Hospitalized with Acute Heart Failure. 急性心力衰竭住院患者表型分型与炎症参数的关系
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-04-30 DOI: 10.18087/cardio.2025.4.n2760
Armağan Kaya, Mustafa Gökçe
{"title":"The Relationship between Phenotypic Classification and Inflammatory Parameters in Patients Hospitalized with Acute Heart Failure.","authors":"Armağan Kaya, Mustafa Gökçe","doi":"10.18087/cardio.2025.4.n2760","DOIUrl":"https://doi.org/10.18087/cardio.2025.4.n2760","url":null,"abstract":"<p><p>Aim    To evaluate the effects of inflammatory parameters on mortality and prognosis in patients who were hospitalized with acute heart failure (AHF) and phenotypically classified.Material and methods    Between December 2020 and August 2021, 240 patients, who were newly diagnosed with acute heart failure (AHF) or those with heart failure and who developed decompensation, were prospectively included in the study. The patients composed four equal groups of 60 patients each according to the phenotypical class of AHF: warm-wet, warm-dry, cold-wet, and cold-dry. Acute phase reactants, namely C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and plasma albumin, were examined at hospitalization, discharge, and 30±7 days after discharge. The reactants were compared between the groups in terms of mortality and prognosis.Results    Univariate analyses showed that, at the time of initial hospitalization, a one-unit increase in albumin decreased the mortality risk 0.794‑fold, while a one-unit increase in CRP increased the mortality risk 1.013‑fold and a one-unit increase in ESR increased the mortality risk 1.026‑fold (p&lt;0.001, p=0.003, and p=0.002, respectively). At discharge, a one-unit increase in albumin decreased the mortality risk 0.85‑fold (p=0.043). However, multivariate analyses showed that, at the time of initial hospitalization, a one-unit increase in albumin decreased the mortality risk 0.803‑fold, while a one-unit increase in the ESR value increased the mortality risk 1.021‑fold (p&lt;0.001 and p=0.049, respectively). Although a statistically significant difference was observed between the warm-dry group and the other groups in terms of in-hospital mortality distributions (p=0.032), there was no statistically significant difference between the groups in terms of out-of-hospital mortality (p&gt;0.050).Conclusion    In AHF patients, low albumin values at initial hospitalization and discharge, high CRP and ESR values at initial hospitalization predict increased mortality.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"16-22"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Multicenter Prospective Observational Study to Examine the Experience of Using Phosphocreatine in Combination Therapy for Heart Failure Caused by Cancer Treatment. Rationale and Design of the Study. 一项多中心前瞻性观察研究,探讨使用磷酸肌酸联合疗法治疗癌症治疗所致心力衰竭的经验。研究的依据和设计。
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-03-31 DOI: 10.18087/cardio.2025.3.n2870
A A Safiullina, V I Potievskaya, M V Vitsenya, I A Cheremisina
{"title":"A Multicenter Prospective Observational Study to Examine the Experience of Using Phosphocreatine in Combination Therapy for Heart Failure Caused by Cancer Treatment. Rationale and Design of the Study.","authors":"A A Safiullina, V I Potievskaya, M V Vitsenya, I A Cheremisina","doi":"10.18087/cardio.2025.3.n2870","DOIUrl":"10.18087/cardio.2025.3.n2870","url":null,"abstract":"<p><p>Enhanced cancer treatment efficacy has resulted in a significant increase in the number of cancer survivors after the cure of malignant tumors. However, cardiovascular morbidity, including chronic heart failure, has become the leading cause of death and decreased life expectancy among cancer survivors. This is due, in particular, to the cardiotoxic effects of anticancer drugs and associated factors. Cardioprotective approaches aim to reduce the incidence and severity of cardiotoxicity through the use of cardioprotective agents (e.g., dexrazoxane), liposomal drug delivery systems (e.g., liposomal doxorubicin), and optimization of drug administration schedules. Reducing the cardiotoxicity of cancer treatments is a clinically important goal. Phosphocreatine-based therapy represents a potentially valuable new strategy in this area. In this regard, the study \"Multicenter prospective observational study to investigate the experience of using phosphocreatine in combination therapy for heart failure caused by cancer treatment\" was initiated. This publication presents the protocol of the observational non-interventional NEOCARD study.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 3","pages":"21-25"},"PeriodicalIF":0.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential of Combination Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes: Focus on Organ Protection. 动脉高血压和糖尿病前期患者的联合药物疗法潜力:关注器官保护。
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-03-31 DOI: 10.18087/cardio.2025.3.n2902
V V Skibitsky, S R Gutova, A V Fendrikova
{"title":"Potential of Combination Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes: Focus on Organ Protection.","authors":"V V Skibitsky, S R Gutova, A V Fendrikova","doi":"10.18087/cardio.2025.3.n2902","DOIUrl":"10.18087/cardio.2025.3.n2902","url":null,"abstract":"<p><p>Aim    To compare the effects of two combined antihypertensive therapies on indices of the structural and functional state of the left ventricular (LV) myocardium and intrarenal vascular resistance in patients with arterial hypertension (AH) and prediabetes.Material and methods    The study included 80 patients with poorly controlled AH and prediabetes who were randomized into two groups: patients in group 1 (n=40) received perindopril at a starting dose of 5 mg/day, sustained-release indapamide 1.5 mg/day, and metformin 1000 mg/day; patients in group 2 (n=40) received perindopril 5 mg/day, moxonidine at a starting dose of 0.2 mg/day, and metformin 1000 mg/day. Subsequently, if necessary, the doses of perindopril and moxonidine were titrated to the maximum permissible ones. Prediabetes was diagnosed based on the results of an oral glucose tolerance test. Ultrasound examination of the heart and renal arteries was performed with a SIEMENS ACUSON X 300 ultrasound apparatus (Korea). Statistical analysis was performed using the Statistica 12.0 software (StatSoft Inc., USA).Results    In both groups after 24 weeks of pharmacotherapy, patients who achieved the target blood pressure had statistically significant and comparable improvements in all studied parameters of the structural and functional state of the LV myocardium and intrarenal vascular resistance. In a comparable number of patients in both groups, the treatment was associated with normalization of the LV myocardial geometry and diastolic function. The combination including moxonidine was associated with a significant decrease in fasting plasma insulin that was more pronounced than with the diuretic treatment.Conclusion    In patients with AH and prediabetes, the combination therapy including perindopril, metformin and moxonidine provided a significant improvement in the structural and functional state of the LV myocardium and intrarenal vascular resistance comparable to the improvement produced by a combination of perindopril, metformin and sustained-release indapamide. The combination of an ACE inhibitor, biguanide and moxonidine may in some cases be a preferred pharmacotherapy option for patients with AH and early carbohydrate metabolism disorders due to the observed significant metabolic benefits.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 3","pages":"26-34"},"PeriodicalIF":0.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Possibilities of Optimizing Drug Therapy for Myocardial Infarction: a Consensus on the Use of Type 2 Sodium-Glucose Co-Transporter Inhibitors. Conciliation Document of the Expert Group. 优化心肌梗死药物治疗的可能性:使用2型钠-葡萄糖共转运蛋白抑制剂的共识。专家组调解文件。
IF 0.5 4区 医学
Kardiologiya Pub Date : 2025-03-31 DOI: 10.18087/cardio.2025.3.n2890
G P Arutyunov, S K Kononov, N I Novitskii, A N Baglikov, A A Shchendrygina, E A Kuzheleva, K A Eruslanova, V A Safronenko, K V Kop'eva, A E Soloveva
{"title":"Possibilities of Optimizing Drug Therapy for Myocardial Infarction: a Consensus on the Use of Type 2 Sodium-Glucose Co-Transporter Inhibitors. Conciliation Document of the Expert Group.","authors":"G P Arutyunov, S K Kononov, N I Novitskii, A N Baglikov, A A Shchendrygina, E A Kuzheleva, K A Eruslanova, V A Safronenko, K V Kop'eva, A E Soloveva","doi":"10.18087/cardio.2025.3.n2890","DOIUrl":"10.18087/cardio.2025.3.n2890","url":null,"abstract":"<p><p>Ischemic heart disease, including previous myocardial infarction (MI), is one of the main causes for the development and progression of heart failure (HF). The presence of HF before MI or the development of HF in the setting of acute coronary catastrophe is an extremely unfavorable prognostic factor leading to a multiple increase in the risk of death and rehospitalization due to HF in the post-infarction period. In 2024, the results of two randomized clinical trials (RCTs) (DAPA-MI and EMPACT-MI) were published, which assessed the effect of sodium-glucose co-transporter type 2 inhibitors (SGLT2i) on clinical outcomes in patients with acute MI. In both studies, the predetermined primary composite endpoint was not achieved. At the same time, it was shown that SGLT2i significantly reduced the risk of hospitalization for HF (empagliflozin) and contributed to the improvement of metabolic outcomes (dapagliflozin). Also, the safety of early initiation of SGLT2i in the acute period of MI was demonstrated. Based on the available results of randomized and observational clinical studies, the working group has substantiated the need for implementing these RCT results into clinical practice and proposed an algorithm for administering SGLT2 to patients with acute MI. Thus, in the presence of compelling anamnestic criteria for the diagnosis or previously diagnosed type 2 diabetes mellitus, and/or chronic kidney disease, and/or HF, continuation or timely initiation of SGLT2i during the hospitalization for index MI is recommended to improve cardiovascular and renal outcomes. Based on the results of RCTs in patients with acute MI and taking into account individual risk factors for the development of HF, the initiation of SGLT2i before discharge may be considered in order to reduce the risk of hospitalization for HF.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 3","pages":"35-47"},"PeriodicalIF":0.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信